Therefore, the selection of cancer patients with high levels of both DRG2 and PD-L1 proteins through a companion diagnostic approach that combines DRG2 expression assessment with PD-L1 IHC assay may improve the therapeutic outcomes with PD-1/PD-L1 ICIs. This evidence concerns the gene CD274 and cancer.